H.R.5629 - Pathway for Biosimilars Act

To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. view all titles (2)

All Bill Titles

  • Short: Pathway for Biosimilars Act as introduced.
  • Official: To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. as introduced.

This Bill currently has no wiki content. If you would like to create a wiki entry for this bill, please Login, and then select the wiki tab to create it.

 
Introduced
 
House
Passes
 
Senate
Passes
 
President
Signs
 

 
03/13/08
 
 
 
 
 
 
 

Latest Action Apr 14, 2008Referred to the Subcommittee on Cour... Related Bills (0) & Issues (29)
3/13/2008--Introduced.Pathway for Biosimilars Act - Amends the Public Health Service Act to allow a person to submit an application for licensure of a biological product based on its similarity to a licensed biological product (the reference product).Requires the Secretary of Health and Hu

Official Summary

3/13/2008--Introduced.
Pathway for Biosimilars Act - Amends the Public Health Service Act to allow a person to submit an application for licensure of a biological product based on its similarity to a licensed biological product (the reference product).
Requires the Secretary of Health and Human Services to approve the application if:
(1) the biological product is biosimilar to the reference product with respect to each condition of use for which the reference product is approved; and
(2) the applicant consents to the inspection of the facility that is the subject of the application. Sets forth requirements for a determination by the Secretary that a biological product is interchangeable with a reference product.
Prohibits a biological product from being evaluated against more than one reference product.
Prohibits licensure under this Act of a biological product containing specified agents or toxins.
Prohibits the Secretary from making approval of an application under this Act effective until 12 yeas after the date on which the reference product was first licensed.
Provides for confidentiality of information received pursuant to this Act.
Sets forth provisions governing patent infringement actions related to this Act.
Deems as patent infringement the submission of a statement under this Act by the applicant setting forth reasons why the making, use, or sale of the biosimilar product would not infringe the patent, or why the patent is invalid or unenforceable, if the purpose of such submission is to obtain approval to engage in the commercial manufacture, use, or sale before the expiration of such patent.


...Read the Rest

FEED
Recent News Coverage

 |  View Top Rated

03/26/08
New US biosimilars bill a disappointing distraction, says GPhA

HR 5629, the bipartisan Pathway for Biosimilars Act introduced in the House by Representatives Anna Eshoo (Democrat, California) and Representative Joe ...

Source: In-PharmaTechnologist.com, UK
Add to My Political Notebook Save to Notebook Rate
03/18/08
California Healthcare Institute Supports Introduction of ...

... March 14, to Congresswoman Anna Eshoo (D-Menlo Park) commending her for the introduction of HR 5629, the “Pathway for Biosimilars Act,” legislation that ...

Source: Earthtimes, UK
Add to My Political Notebook Save to Notebook Rate
FEED
Recent Blog Coverage

View All (46)  |  View Top Rated

01/04/09
Patent Docs: Top Stories of 2008: #9 to #6

Five follow-on biologics bills were introduced during the 110th Congress: H.R. 1956 (which provides twelve years of data exclusivity and two years of market exclusivity), S. 1695 and H.R. 5629 (which provide four years of data ...

Source: Patent Docs
Add to My Political Notebook Save to Notebook Rate
01/02/09
Patent Docs: Teva CEO Predicts Passage of Follow-on Biologics Bill ...

We also reported last summer that the Biotechnology Industry Organization (BIO) indicated that either H.R. 1956 (providing fourteen years of exclusivity), H.R. 5629 (providing twelve years of exclusivity), or S. 1695 (also providing ...

Source: Patent Docs
Add to My Political Notebook Save to Notebook Rate
12/14/08
GoozNews: Biosimilars, Biogenerics Not the Same

Anna Eshoo’s H.R.5629 each call for testing drugs for safety, purity and “potency.” The FDA uses potency as a synonym for efficacy. In other words, all three bills would mandate clinical trial effectiveness testing – the expensive ...

Source: GoozNews
Add to My Political Notebook Save to Notebook Rate

Bill's Views

  • Today: 1
  • Past Seven Days: 13
  • All-Time: 1,176

-%

Users Support Bill

in favor / opposed
Write Your Representative
Track with MyOC

OpenCongress is a free and open-source joint project of two non-profit organizations, the Participatory Politics Foundation and the Sunlight Foundation.